[ad_1]
|
Another new vaccine from the national crown is expected to be available next year. |
The first domestic chimpanzee adenovirus vector novel corona vaccine industrialization base was established in Beijing Daxing |
On December 27, the first industrialization base of the chimpanzee domestic adenovirus vector novel corona vaccine project was officially installed at Daxing Biomedical Industrial Park. The novel chimpanzee adenovirus vector coronavirus vaccine was jointly developed by the team of Professor Zhang Linqi from Tsinghua University, the team of Professor Zhou Dongming from Tianjin Medical University and Yunnan Watson Biotechnology Co., Ltd.Ha passed the animal safety and efficacy test and will soon be nominated for clinical trials. And it is expected to be mass produced next year.
After the outbreak of the new corona pneumonia epidemic, China has established five routes of vaccine research and development technology: inactivated vaccines, adenovirus vector vaccines, attenuated influenza virus vector vaccines, recombinant protein vaccines and nucleic acid vaccines. “What we are doing is a vaccine with chimpanzee adenovirus as a carrier.” Zhang Linqi introduced that the chimpanzee adenovirus vector has many advantages in terms of safety, immunogenicity, production, transport and storage on a large scale.
At the beginning of the outbreak of the new corona pneumonia epidemic earlier this year, the team began to cooperate in investigating the new corona vaccine. In May, after strenuous efforts, the independently copyrighted chimpanzee adenovirus vector vaccine developed by the team entered the animal safety and efficacy testing stage.
The key mechanism of the vaccine is to induce an efficient immune response, so that the body keeps the new coronavirus away. Zhang Linqi pointed out that the novel coronavirus protein S must bind to the human ACE2 protein before the virus can invade the human body. “If protein S is compared to a ‘key’ and the human body’s ACE2 is regarded as the ‘lock’ of the door, then the new corona virus enters the human body using the ‘key’ to open the ‘lock’ of human ACE2, and then it enters the cell and begins to replicate in large numbers. Cause damage, “said Zhang Linqi.
In previous studies, the research team collected protein S and loaded it into the modified chimpanzee adenovirus vector. When the carrier was loaded with protein S and transported into human cells, the human immune system quickly assembled a “special killer” specifically for protein S. Sex weapons “- new antibodies to the coronavirus.
“When the new corona virus attacks, the human body’s special weapon of death is ready to kill the virus outside of human cells and achieve immune protection against the new corona virus.” Zhang Linqi specifically mentioned that the chimpanzee adenovirus vector has been modified. It is a “one-way car”, it will disintegrate on its own after completing the task of transporting protein S, and it will not replicate “chaotic” in the human body.
Because it captures the single receptor key point for the new coronavirus to enter the human body, the characteristic of this type of vaccine is that the cells can produce a precise immune response and are more targeted. Zhang Linqi told the Chinese Journal of Science that the adenovirus vector used in the new vaccine developed by the team comes from the rare chimpanzee serum. The main reason is that there are generally no pre-existing neutralizing antibodies against chimpanzee adenovirus in the human body. “The biggest advantage of a vaccine that uses this virus as a carrier is that the adverse reactions after vaccination are small and it has the advantages of high productivity and strong immunity.”
“Currently, no side effects of the vaccine have been observed in animals.” Zhang Linqi revealed that the vaccine is expected to be applied for clinical trials at home and abroad in late December. “Phase III clinical trials to verify the efficacy of the vaccine should be conducted in foreign pandemic areas. Like several other new coronavirus vaccines developed, we are also faced with the situation that no patient in China is participating in clinical trials of phase III “.
Zhang Linqi said that, from the perspective of the long-term epidemic of the novel coronavirus, the research and development of the first new coronavirus vaccine has achieved results and has shown good safety and efficacy, but it is necessary to continue to observe the protection long-term. As a second follower, your team will focus more on the comprehensive capabilities of vaccines, including efficacy, safety, shelf life, scale, and accessibility.
It is reported that once the vaccine is successfully developed, it will be mass-produced at Watson’s new crown vaccine base in Daxing. Now start building production workshops and by the middle of next year the vaccine can be commercialized on a large scale.
Copyright Statement: For all works marked “Source: China Science News, Science Net, Science News Magazine” on this website, please indicate the source and author at the top of the text and do not make material changes to the content; WeChat is public For new media platforms such as No. and Toutiao No., please contact reprint authorization. Email: [email protected].
